Xiong W, Hietala SF, Nyberg J, Papasouliotis O, et al. Exposure-response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations. Cancer Chemother Pharmacol 2022;90:53-69.
PMID: 35771259